Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.

@article{Lusher1993RecombinantFV,
  title={Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.},
  author={J. Lusher and Steven Arkin and Charles F Abildgaard and Robert S. Schwartz},
  journal={The New England journal of medicine},
  year={1993},
  volume={328 7},
  pages={453-9}
}
BACKGROUND Although methods of viral attenuation in plasma-derived clotting-factor concentrates have improved, there is still a possibility that such concentrates may transmit certain blood-borne viruses. For this reason, the use of recombinant DNA-derived factor VIII (which is virus-free) to treat hemophilia A has generated considerable interest. METHODS We conducted a multicenter trial in previously untreated children with hemophilia A. They received recombinant factor VIII for all… CONTINUE READING

From This Paper

Topics from this paper.
120 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 120 extracted citations

Similar Papers

Loading similar papers…